- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Opinion
Video
Differentiating Clinical Markers in Vitiligo: Managing Unstable Disease and Depigmented Macules
Author(s):
An expert on vitiligo discusses the case of a 49-year-old woman with a history of vitiligo who presents with depigmented macules on her abdomen, thighs, and forearms that developed over 2 months.
Video Player is loading.
Video content above is prompted by the following questions:
- What is your impression of this case?
- What challenges does this case present with, if any?
- What considerations should be taken into account when treating a patient with worsening vitiligo involving large BSA?
- In your clinical practice, what role does the amount of BSA coverage play in your treatment decisions?
- Are there BSA limits you adhere to when treating patients with widespread vitiligo?
- What is your approach to the patient with worsening vitiligo that involves high BSA?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Determining Follow-Up Approach in Melanoma Based on GEP Risk Level
Key Takeaways on GEP Testing in Melanoma and SCC
De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC
Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma
Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma
Utility of Molecular Testing in Skin Cancer Risk Assessment
Limitations and Challenges in Skin Cancer Staging Systems
Laboratory Monitoring for JAK Inhibitors and Key Takeaways
Options for Eyebrow and Eyelash Regrowth in a 32-Year-Old Female With Alopecia Areata
Discussing Efficacy and Safety of JAK Inhibitors With Patients and Caregivers
Related Content
